Sucampo Pharma Llc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SUCAMPO PHARMA LLC, and what generic alternatives to SUCAMPO PHARMA LLC drugs are available?
SUCAMPO PHARMA LLC has two approved drugs.
There are five US patents protecting SUCAMPO PHARMA LLC drugs.
There are seventy patent family members on SUCAMPO PHARMA LLC drugs in nineteen countries and five supplementary protection certificates in five countries.
Summary for Sucampo Pharma Llc
International Patents: | 70 |
US Patents: | 5 |
Tradenames: | 2 |
Ingredients: | 2 |
NDAs: | 2 |
Drugs and US Patents for Sucampo Pharma Llc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-002 | Apr 29, 2008 | AB | RX | Yes | No | 8,338,639 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-002 | Apr 29, 2008 | AB | RX | Yes | No | 8,748,481 | ⤷ Sign Up | ⤷ Sign Up | |||
Sucampo Pharma Llc | RESCULA | unoprostone isopropyl | SOLUTION/DROPS;OPHTHALMIC | 021214-001 | Aug 3, 2000 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Sucampo Pharma Llc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-002 | Apr 29, 2008 | 7,417,067 | ⤷ Sign Up |
Sucampo Pharma Llc | RESCULA | unoprostone isopropyl | SOLUTION/DROPS;OPHTHALMIC | 021214-001 | Aug 3, 2000 | 5,001,153 | ⤷ Sign Up |
Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-001 | Jan 31, 2006 | 8,088,934 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for SUCAMPO PHARMA LLC drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Capsules | 8 mcg and 24 mcg | ➤ Subscribe | 2012-08-20 |
➤ Subscribe | Ophthalmic Solution | 0.15% | ➤ Subscribe | 2014-05-12 |
International Patents for Sucampo Pharma Llc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Taiwan | 200612901 | ⤷ Sign Up |
Russian Federation | 2007111908 | ⤷ Sign Up |
Brazil | PI0707334 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Sucampo Pharma Llc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1315485 | 132016000025193 | Italy | ⤷ Sign Up | PRODUCT NAME: LUBIPROSTONE O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(AMITIZA); AUTHORISATION NUMBER(S) AND DATE(S): PL 21341/0003, 20120910;043833019-021, 20150526 |
2298314 | 92826 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: LUBIPROSTONE, INCLUANT LES SELS PHARMACEUTIQUEMENT ACCEPTABLES, LES ESTERS OU LES AMIDES DE LA LUBIPROSTONE. FIRST REGISTRATION: 20120910 |
1315485 | 2015/028 | Ireland | ⤷ Sign Up | PRODUCT NAME: LUBIPROSTONE AND PHARMACEUTICALLY ACCEPTABLE SALTS FOR LUBIPROSTONE.; NAT REGISTRATION NO/DATE: PA148/002/001 20150213; FIRST REGISTRATION NO/DATE: PL21341/0003-0001 20120910 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.